axSpA Decision Tool
Expert Guidance on Managing Axial Spondyloarthritis: An Interactive Perspective

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: March 04, 2025

Expiration: March 03, 2026

About This Tool & Disclaimer

Expert Guidance on Managing Axial Spondyloarthritis: An Interactive Perspective 

Clinical Care Options, LLC, is grateful to Philip Mease, MD, MACR; Alexis Ogdie, MD, MSCE; Atul Deodhar, MD, MRCP; Julia Swafford, PA-C, DFAAPA; and Cayla Alexander, DNP, ARNP; who provided expert guidance, knowledge, and support in the development of this Interactive Decision Support Tool.

Note: The current tool was created in December 2024 and reflects the guidelines available at that time.

The goal of the tool is to educate clinicians on making optimal management choices for monitoring or treating individuals with active axial spondyloarthritis infection based on expert opinion and current ACR/SAA/SPARTAN and ASAS-EULAR practice guidelines in the United States and Europe.

A series of questions allow the participant to select individual patient characteristics that are necessary to consider when making management choices. These characteristics include predominant disease features, comorbidities or presence of risk factors, and previous treatment failures.

It should be noted that these are not exclusive characteristics when selecting optimal treatment for patients with axial spondyloarthritis. Other considerations that are not included in this tool, such as the presence of various comorbidities and any concurrent medications, should also be considered, when appropriate for making management decisions.

This tool assumes we have a “standard” patient with active axial spondyloarthritis but with no additional features or specific comorbidities that would affect treatment choice other than those described when entering the patient details. Based on the characteristics entered, the tool will display expert recommendations for that specific patient case.

For additional information on best practices in the management of patients with axial spondyloarthritis, please see other components of this program titled, "Case Challenges in Spondyloarthritis: Can You Crack the Code With Advanced Targeted Therapies for Patients With Psoriatic Arthritis and Axial Spondyloarthritis?​" including ClinicalThought commentaries, downlodable slides, live events, and webcasts.

This program is supported by an educational grant from Lilly.

Produced in collaboration with the Society for Physician Associates in Rheumatology (SPAR).

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Philip Mease, MD, MACR: consultant: AbbVie, Acelyrin, Amgen, Bristol Myers Squibb, Cullinan Biotech, Inmagene, Janssen, Lilly, MoonLake, Novartis, Pfizer, Takeda, UCB; researcher: AbbVie, Acelyrin, Amgen, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, UCB; data and safety monitoring board: Genascence; speaker: AbbVie, Amgen, Janssen, Lilly, Pfizer, UCB.​

Alexis Ogdie, MD, MSCE: consultant: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Gilead, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Takeda, Treg, UCB; researcher (paid to institution): Abbvie, Janssen, Novartis, Pfizer; researcher: Amgen.​

Atul Deodhar, MD, MRCP: researcher: Bristol Myers Squibb, Janssen, Lilly, MoonLake, Novartis, Pfizer, UCB; consultant/advisor/speaker: Bristol Myers Squibb, Janssen, Lilly, MoonLake, Novartis, Pfizer, UCB.

Cayla Alexander, DNP, ARNP: consultant/advisor/speaker: Novartis.

Julia Swafford, PA-C, DFAAPA, has no relevant financial relationships to disclose.

©2025 Clinical Care Options, LLC. All rights reserved.

Access to and use of this Interactive Decision Support Tool titled, “Expert Guidance on Managing Axial Spondyloarthritis: An Interactive Perspective” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate rheumatologists, nurse practitioners, and physician associates who are involved in the care of patients with axSpA on making optimal management choices for monitoring or treating individuals with axSpA. The information provided is based on the GRAPPA and EULAR guideline recommendations and expert guidance of Philip Mease, MD, MACR; Alexis Ogdie, MD, MSCE; Atul Deodhar, MD, MRCP; Julia Swafford, PA-C, DFAAPA; and Cayla Alexander, DNP, ARNP.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the "Expert Guidance on Managing Axial Spondyloarthritis: An Interactive Perspective” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

©2025 Clinical Care Options, LLC. All rights reserved.

Program Content